MedTrace Logo

QuiremSpheres Observational Study

NCT03563274 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2021-03-29

No results posted yet for this study

Summary

The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT and allocated to this treatment by a multidisciplinary tumor board.

Conditions

  • Liver, Cancer of, Non-Resectable

Interventions

DEVICE

Selective Internal Radiation Therapy with QuiremSpheres®

The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT and allocated to this treatment by a multidisciplinary tumor board.

Sponsors & Collaborators

  • Terumo Europe N.V.

    lead INDUSTRY

Principal Investigators

  • Dragica Paunovic, MD · Chief Medical Officer at Terumo Europe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-21
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • Germany
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03563274 on ClinicalTrials.gov